Kanis J A, McCloskey E V, Johansson H et al, “A reference standard for the description of osteoporosis”, Bone 2008 Mar;42(3):467-75.
Lewiecki E M, Laster A J, “Clinical review: Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry”, J Clin Endocrinol Metab. 2006 Nov;91(11)4215-22.
Watts NB, “The fracture risk assessment tool (FRAX): applications in clinical practice”, J Womens health, 2011;Apr;20(4):525-31.
Huntjens K, van Geel T, van den Bergh J et al, “Fracture Liaison Service: Impact on subsequent nonvertebral fracture incidence and mortality”, J Bone Joint Surg Am, 2014; 96:e29(1-8).
Mirza F, Canalis E, “Secondary osteoporosis: pathophysiology and management”, Eur J Endocrinol. 2015 Sep;173(3):R131-R151.
Devogelaer JP, Goemare S, Boonen S, et al, “Evidence-based guidelines for the prevention and treatment of glucocorticoid- induced osteoporosis: a consensus document of the Belgian Bone Club”, Osteop Int, 2006;Jan;17(1):8-19.
Reginster J, “Antifracture efficacy of currently available therapies for postmenopausal osteoporosis”, Drugs, 2011;71(1);65-78.
Simpson E L, Martyn-St James M, Hamilton J et al, “Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis”, Bone 2020 Jan;130:115081.
Hauselmann HJ, Rizzoli R, “A comprehensive review of treatments for postmenopausal osteoporosis”, Osteop Int, 2003;14:2-12.
Avenell A, Mak JCS, O’Connell D, “Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men (Review)”, Cochrane Database of Systematic Reviews, 2014;Issue 4.
McClung M, Harris S et al, “Bisphosphonate therapy for osteoporosis; benefits, risks and drug holiday”, Am J Med, 2013;Jan;126(1):13-20.
Adler R, Ghada El-Hajj F, Bauer D et al, “Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research”, J Bone Miner Res, 2016;Jan. Vol 31, no 1, 16-35
Wells GA, Cranney A, Peterson J, et al, “Alendronate for the primary and secondary prevention of osteoporotic fractures in post- menopausal women”, Cochrane Database Syst Rev, 2008;Jan23;(1):CD001155. Review.
Wells G, Cranney A, Peterson J, et al, “Risedronate for the primary and secondary prevention of osteoporotic fractures in post- menopausal women”, Cochrane Database Syst Rev, 2008;Jan23;(1):CD004523. Review.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al, “Zoledronic acid and clinical fractures and mortality after hip fracture”, N Engl J Med, 2007;357(18):1799-809.
Devogelaer JP et al, “Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis”, Osteoporos Int, 2007;18(9):1211- 8.
Saito T, Sterbenz J.M. Malam S et al, “Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis”, Osteop Int, 2017;28;3289-3300.
Cummings SR, San Martin J, McClung MR et al, “FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteo- porosis”, N Engl J Med, 2009;361(8):756-65. Erratum in: N Engl J Med. 2009;Nov 5;361(19):1914.
Smith MR, Egerdie B, Hernández Toriz N et al, “Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer”, N Engl J Med, 2009;361(8):745-55.
Stopeck AT, Lipton A, Body JJ et al, “Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study”, J Clin Oncol, 2010;28(35):5132-9.
Kahn A A, Morrison A, Hanley D A et al, “Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus”; J Bone Miner Res. 2015 Jan;30(1):3.23.
Schilcher J, Michaëlsson K, Aspenberg P, “Bisphosphonate use and atypical fractures of the femoral shaft”, N Engl J Med, 2001;362:1728- 37.
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B, Bastin S, Grey A, Reid IR, Gamble G, Horne A.N Engl J Med. 2025 Jan 16;392(3):239-248. doi: 10.1056/NEJMoa2407031
Cranney A, Papaioannou A, Zytaruk N, et al, “Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review”, CMAJ, 2006;175(1):52-9. Review.
Cranney A, Tugwell P, Zytaruk N,et al, “Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis”, Endocr Rev, 2002;Aug;23(4):524-8. Review.
Cosman F, Crittenden D B, Ferrari S et al, “FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab”, J Bone Miner Res. 2018 Jul;33(7)1219-1226.
Fang Lv, Xiaoling c, Wenjia Y et al, “Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis”, Bone 2020 Jan;130:115121.
Läkemedelsverkets rekommendationer: Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation Läkemedelsverket Läkemedelsverket (lakemedelsverket.se)
